Shearman & Sterling advised the underwriters in connection with the follow-on public offering by Y-mAbs Therapeutics, Inc.’s 2,804,878 shares of common stock at a public offering price of $41 per share, resulting in aggregate gross proceeds to Y-mAbs of approximately $115 million. The offering consisted of 2,804,878 shares sold by Y-mAbs, including 365,853 shares sold pursuant to the exercise in full of the option to purchase additional shares granted to the underwriters by Y-mAbs in connection with the offering.
J.P. Morgan, Morgan Stanley and BofA Securities acted as joint book-running managers for the offering and H.C. Wainwright & Co. and Kempen & Co. acted as lead co-managers.
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.
The Shearman & Sterling team below included associate Katie Byun (New York-Capital Markets).